Tidmarsh, who has founded and served as CEO of several biotech companies, will lead a crucial FDA division that reviews the majority of new drug applications.
Tidmarsh, who has founded and served as CEO of several biotech companies, will lead a crucial FDA division that reviews the majority of new drug applications.